Plasma atrial natriuretic peptide in essential hypertension after treatment with terazocin

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 28, Issue 2, 2003, Pages 143-146

  Kotridis, P ^a   Kokkas, Basile ^a,c   Kyriakou, P ^a   Karamouzis, M ^a   Salpigidis, G ^b   Karantona, C ^a   Karadoumanis, J ^a   Ginis, T ^a   Goulis, O ^a   Papadopoulos, P C ^a   Vakalopoulos, C ^b   Sakantamis, G ^a   Dimitriadou, A ^a   Mirtsou Fidani, V ^a   Papadopoulos, C L ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b Ippokration Hospital Thessaloniki   (Greece)

^c NONE   (Greece)

Author keywords

Atrial natriuretic peptide; Ca2+ blockers; Hypertension; Terazocin

Indexed keywords

ATRIAL NATRIURETIC FACTOR; TERAZOSIN;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; ESSENTIAL HYPERTENSION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART WORK; HUMAN; MALE; PROTEIN DETERMINATION; SYSTOLIC BLOOD PRESSURE;

EID: 10744233689     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03190503     Document Type: Article

References (19)

1. Papadopoulos C.L, Kokkas B, Kotridis P, Gitsios C, Sakadamis G, Kanonidis I, Faitatziadis D, Pilis A, Theodoridis E, Paradelis A. (1995): Plasma atrial natriuretic peptide in essential hypertension after angiotensin coverting enzyme inhibition. Intern. J. Angiology, 4, 44-45
2. 1-blocker bisoprolol on atrial natriuretic peptide plasma levels in hypertensive patients. Intern. J. Angiology, 4, 165-168
3. 2-agonist celiprolol on atrial natriuretic peptide plasma levels in hypertensive patients. Cardiovasc. Drugs Ther., 12, 345-346
4. Papadopoulos C.L, Kokkas B, Anogiannakis G. (2000): Beta blockers and atrial natriuretic peptide (ANP) in hypertension. Intern. J. Immunopathol. Pharmacol., 13, 107-110
5. Kotridis P., Kokkas B., Karamouzis M., Sakadamis G., Kanonidis I., Dadous G., Karadona G., Gouli O., Karadoumanis J., Papadopoulos P.C., Papadopoulos C.L. (2002): Plasma atrial natriuretic peptide in essential hypertension after treatment with irbesartan. Blood Pressure, 11, 91-94,
6. 1-selective blocker. J. Clin. Pharmacol., 33, 878-888
7. Hama J, Nagata S, Takenaka T, Kino S, Shimada M, Horiuchi M, Katori R.I. (1995): Atrial natriuretic peptide and antihypertensive action due to beta - blockade in essential hypertensive patients. Angiology, 46, 511-516
8. Kokkas B, Kotridis P, Karamouzis M, Kanonidis I, Sakadamis G, Dadous G, Haritos S, Kyriakou P, Theodossiadis I, Papadopoulos P.C, Mirtsou-Fidani V, Papadopoulos C.L. (2002): Plasma atrial natriuretic peptide levels in essential hypertension after treatment with verapamil. Eur. J. Drug Metab. Pharmacokin., 27, 45-48
9. Iwasaki T, Niwa A, Shinoda T, Ishihara M, Aizawa T, Yamada T. (1989): Effects of calcium antagonists and nitroglycerin on atrial natriuretic peptide in normal subjects and patients with essential hypertension. Angiology, 40, 24-28
10. Hollenberg M, Plum J, Heering P, Kutkuthn H, Grabensee B. (1991): Influence of betaxolol on renal function and atrial natriuretic peptide in essential hypertension. J. Hypertension, 9, 819-824
11. Geller D, Currie M, Wakitani K. (1984): Atriopeptides. Biochem. Biophys. Res. Commun., 120, 333-338
12. Rosmalen F, Horman J, Tan A. (1988): A sensitive radioimmunoassay of atrial natriuretic peptide in human plasma; some guidelines for clinical applications. Z. Kardiol. 1988, 77 (Suppl.2), 20-25
13. Karamouzis M, Mandroukas K, Deligiannis D. (1994): Changes in atrial natriuretic peptide (a-ANP) in long distance swimmers. Clin. Chem. Enzym. Comms., 6, 191-195
14. Shields P, Glembotski C. (1989): Regulation of atrial natriuretic factor-secretion from neonatal rat primary atrial cultures by activators of protein kinases A and C. Biol. Chem., 264, 9322-9328
15. Semplicini A, Valle R, Serena L, Fazari G, Fontebasso A, Gebbin A, De Toni R, Pessina A. (1994): Long-term alpha-1 adrenoceptor blockade does not affect plasma atrial natriuretic peptide in hypertensive patients. Horm. Metab. Res., 26, 207-208
16. Valle R, Semplicini A, Serena L, Gebbin A, Fontebasso A, Gerardi G, DeToni R, Pessina A. (1996): Pressure and metabolic effects of terazocin in essential hypertension. Cardiologia, 39, 421-424
17. Yoshimoto T, Naruse M, Naruse K, Shionoya K, Tanaka M, Tanave A, Hagiwara H, Hirose S, Muraki T, Demusa H. (1996): Angiotensin II-depended down regulation of vascular natriuretic peptide type C receptor gene expression in hypertensive rats. Endocrinology, 137, 1102-1107
18. Yoshimoto T, Naruse M, Irie K, Tanabe A, Seki T, Tanaka M, Imaki T, Naruse K, Muraki T, Matsuda Y, Demura H. (1998): Beta-adrenergic antagonist propranolol potentiates hypertensive action of natriuretic peptides. Eur. J. Pharmacol., 12, 61-66
19. Yoshimoto T, Naruse M, Tanabe A, Naruse A, Seki T, Imaki T, Muraki T, Matsuda Y, Damura H. (1998): Potentiation of natriuretic peptide action by beta-adrenergic blocker carvedilol in hypertensive rats: a new antihypertensive mechanism. Endocrinology, 139, 81-88